Skip to content

Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients

Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030812
Enrollment
Unknown
Registered
2020-03-15
Start date
2020-01-31
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:none

Sponsors

Shanghai Ninth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years Chinese people; 2. Clinical diagnosis of 2019 - nCoV suspected cases: clinical diagnosis of 2019 - nCoV suspected cases: according to the national health committee office of the general office of the state administration of traditional Chinese medicine on February 3, 2020 promulgated the new coronavirus infection pneumonia diagnosis and treatment scheme (trial version 5) notice, will be suspected cases are defined as any article 1 has a history of epidemiology, conform to the clinical manifestation of 2:1) history of epidemiology: in 14 days before the onset of Wuhan city and surrounding areas, or other cases reported history of history of travel or live in the community; In the 14 days before onset, the patient had been exposed to fever or respiratory symptoms from wuhan city and surrounding areas or from the case reporting community.Cluster disease; With the new coronavirus infection has a history of contact, the new coronavirus infection refers to the pathogen nucleic acid test positive.(2) clinical manifestations: fever and/or respiratory symptoms;The imaging features of pneumonia were as follows: multiple small patches and stromal changes were observed in the early stage, and the lung exhalation was obvious. Then, multiple ground glass and infiltrating shadows were found in both lungs. 3. In severe cases, lung consolidation could occur, and pleural effusion was rare.The total number of white blood cells in the early stage of the disease is normal or decreased, or the lymphocyte count is reduced.The clinical diagnosis was confirmed as 2019-ncov cases: based on the suspected cases, sputum, pharyngeal swab, secretions of the lower respiratory tract and other specimens were tested for positive nucleic acid of the novel coronavirus by real-time fluorescence rt-pcr. Or virus gene sequencing, and known new coronavirus highly homologous.Mild cases or severe cases were included in the study.

Exclusion criteria

Exclusion criteria: Unsigned or unwilling to sign informed consent

Design outcomes

Primary

MeasureTime frame
Single cell sequencing;

Countries

China

Contacts

Public ContactXu Jie

Shanghai Ninth People's Hospital

dr.xu@aliyun.com+86 13501722091

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026